查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1356558

膀胱癌診斷市場報告：至2030年的趨勢、預測與競爭分析

Bladder Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

膀胱癌診斷的趨勢和預測

預計到2030年，全球膀胱癌診斷市場將達到 48 億美元，2024年至2030年年複合成長率為 7.8%。這個市場的主要促進因素是人們對膀胱相關疾病的認知不斷提高，老年人口不斷增加，以及對電腦斷層掃描和磁振造影等先進診斷技術的需求不斷增加。全球膀胱癌診斷市場的未來前景廣闊，醫院、診所和癌症中心市場存在商機。

膀胱癌診斷市場洞察

Lucintel 預測，有效的切片檢查技術，更增加使用切片檢查進行高級成像以及對經尿道膀胱腫瘤切除術的日益偏好將導致切片檢查有望實現最高成長。

由於膀胱癌入院人數迅速增加以及醫療專業人員的可用性，醫院可能仍然是最大的區隔。

由於擁有成熟的醫療基礎設施，領先的生技藥品公司以及主要參與者，預計北美將在預測期內實現最高的成長。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.未來哪個細分市場成長較快？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球膀胱癌診斷市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球膀胱癌診斷市場趨勢（2018-2023）與預測（2024-2030）
  • 按測試類型分類的全球膀胱癌診斷市場
    • 尿液檢查
    • 膀胱鏡檢查
    • 切片檢查
    • 影像檢查
  • 按癌症類型分類的全球膀胱癌診斷市場
    • 膀胱移行細胞癌
    • 膀胱鱗狀細胞癌
    • 其他
  • 依最終用途行業分類的全球膀胱癌診斷市場
    • 醫院
    • 診所
    • 癌症中心
    • 其他

第4章 2018-2030年市場趨勢及預測分析，依地區

  • 全球膀胱癌診斷市場，依地區
  • 北美膀胱癌診斷市場
  • 歐洲膀胱癌診斷市場
  • 亞太膀胱癌診斷市場
  • 其他區域膀胱癌診斷市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按測試類型分類的全球膀胱癌診斷市場成長機會
    • 全球膀胱癌診斷市場成長機會（按癌症類型）
    • 全球膀胱癌診斷市場最終用途產業的成長機會
    • 全球膀胱癌診斷市場成長機會，依區域
  • 全球膀胱癌診斷市場新趨勢
    • 新產品開發
    • 全球膀胱癌診斷市場的產能擴張
    • 全球膀胱癌診斷市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Ameritech Diagnostic Reagent
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hofmann-La Roche
  • GlaxoSmithKline
  • Novartis International
  • Pfizer
  • Abbott
  • Endo Pharmaceuticals
  • Johnson & Johnson
簡介目錄

Bladder Cancer Diagnostic Trends and Forecast

The future of the global bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets. The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing awareness of bladder related diseases, increasing number of geriatric popuation, and rising demand for advanced diagnostic technologies like computed tomography scan and magnetic resonance imaging.

A more than 150-page report is developed to help in your business decisions.

Bladder Cancer Diagnostic by Segment

The study includes a forecast for the global bladder cancer diagnostic by test type, cancer type, end use industry, technology, and region.

Bladder Cancer Diagnostic Market by Test Type [Shipment Analysis by Value from 2018 to 2030]:

  • Urine Lab Tests
  • Cystoscopy
  • Biopsy
  • Imaging Tests

Bladder Cancer Diagnostic Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Others

Bladder Cancer Diagnostic Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Cancer Centers
  • Others

Bladder Cancer Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Bladder Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bladder cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bladder cancer diagnostic companies profiled in this report include-

  • Ameritech Diagnostic Reagent
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hofmann-La Roche
  • Glaxosmithkline
  • Novartis International
  • Pfizer
  • Abbott
  • Endo Pharmaceuticals
  • Johnson & Johnson

Bladder Cancer Diagnostic Market Insights

Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its substantial use for effective biopsy technique and advanced imaging and rising preference for transurethral resection of bladder tumor approach.

Hospital will remain the largest segment due to surge in bladder cancer hospitalizations and substantial availability of healthcare experts in this setting.

North America is expected to witness highest growth over the forecast period due to exisitence of well-established healthcare infrastructure, availability of major biologics companies, and presence of key players in the region.

Features of the Global Bladder Cancer Diagnostic Market

Market Size Estimates: Bladder cancer diagnostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Bladder cancer diagnostic market size by test type, cancer type, end use industry, and region. in terms of value ($B).

Regional Analysis: Bladder cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different test types, cancer typse, end use industries, and region.s for the bladder cancer diagnostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bladder cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the bladder cancer diagnostic market size?

Answer: The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030.

Q.2. What is the growth forecast for bladder cancer diagnostic market?

Answer: The global bladder cancer diagnostic market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the bladder cancer diagnostic market?

Answer: The major drivers for this market are growing awareness of bladder related diseases, increasing number of geriatric popuation, and rising demand for advanced diagnostic technologies like computed tomography scan and magnetic resonance imaging.

Q.4. What are the major segments for bladder cancer diagnostic market?

Answer: The future of the bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets.

Q.5. Who are the key bladder cancer diagnostic market companies?

Answer: Some of the key bladder cancer diagnostic companies are as follows:

  • Ameritech Diagnostic Reagent
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hofmann-La Roche
  • GlaxoSmithKline
  • Novartis International
  • Pfizer
  • Abbott
  • Endo Pharmaceuticals
  • Johnson & Johnson

Q.6. Which bladder cancer diagnostic market segment will be the largest in future?

Answer: Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its substantial use for effective biopsy technique and advanced imaging and rising preference for transurethral resection of bladder tumor approach.

Q.7. In bladder cancer diagnostic market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to exisitence of well-established healthcare infrastructure, availability of major biologics companies, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the bladder cancer diagnostic market by test type (urine lab tests, cystoscopy, biopsy, and imaging test), material (transitional cell bladder cancer, squamous cell bladder cancer, and others), end use industry (hospitals, clinics, cancer center, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Bladder Cancer Diagnostic Market: Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Bladder Cancer Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Bladder Cancer Diagnostic Market by Test Type
    • 3.3.1: Urine Lab Tests
    • 3.3.2: Cystoscopy
    • 3.3.3: Biopsy
    • 3.3.4: Imaging Tests
  • 3.4: Global Bladder Cancer Diagnostic Market by Cancer Type
    • 3.4.1: Transitional Cell Bladder Cancer
    • 3.4.2: Squamous Cell Bladder Cancer
    • 3.4.3: Others
  • 3.5: Global Bladder Cancer Diagnostic Market by End Use Industry
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: Cancer Centers
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Bladder Cancer Diagnostic Market by Region
  • 4.2: North American Bladder Cancer Diagnostic Market
    • 4.2.1: North American Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
    • 4.2.2: North American Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
  • 4.3: European Bladder Cancer Diagnostic Market
    • 4.3.1: European Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
    • 4.3.2: European Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
  • 4.4: APAC Bladder Cancer Diagnostic Market
    • 4.4.1: APAC Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
    • 4.4.2: APAC Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
  • 4.5: ROW Bladder Cancer Diagnostic Market
    • 4.5.1: ROW Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
    • 4.5.2: ROW Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by Test Type
    • 6.1.2: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by End Use Industry
    • 6.1.4: Growth Opportunities for the Global Bladder Cancer Diagnostic Market Region
  • 6.2: Emerging Trends in the Global Bladder Cancer Diagnostic Market
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Bladder Cancer Diagnostic Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bladder Cancer Diagnostic Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Ameritech Diagnostic Reagent
  • 7.2: Bristol-Myers Squibb
  • 7.3: Eli Lilly
  • 7.4: F. Hofmann-La Roche
  • 7.5: GlaxoSmithKline
  • 7.6: Novartis International
  • 7.7: Pfizer
  • 7.8: Abbott
  • 7.9: Endo Pharmaceuticals
  • 7.10: Johnson & Johnson